Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 115.60
Updated 08/12/2018
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 871,699
High $ 0
Low $ 114.40
Open $ 119.83
ISIN
Prev close $ 121.04
# of shares 223.10M
Market cap 25,790M USD
Intraday

Market closed
Alexion Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  115.60 -7.9% Stock price decreasing -6.4% Stock price decreasing -1.9% Stock price decreasing -2.3% Stock price decreasing 1.0% Stock price increasing
Powered by TradingView

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, which is the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders, and was recently approved in general myasthenia gravis. Strensiq and Kanuma target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
10 December 2018 11:45:08
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB3 - 2018-12-10 12:45:08 - 2018-12-10 11:45:08 - 1000 - Website: OKAY